Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2012 - 2022)

Ani Pharmaceuticals has disclosed Current Deferred Revenue across 8 years of filings, most recently posting $116000.0 for Q1 2022.

• In Q1 2022, Current Deferred Revenue rose 16.0% year-over-year to $116000.0; the TTM figure through Mar 2022 stood at $116000.0 (up 16.0% YoY), while the FY2021 annual figure was $100000.0, changed 0.0% from the prior year.
• Current Deferred Revenue came in at $116000.0 for Q1 2022 at Ani Pharmaceuticals, up from $100000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $735000.0 in Q3 2018 to a low of $100000.0 in Q4 2020.
• Average Current Deferred Revenue over 5 years is $319666.7, with a median of $125000.0 recorded in 2020.
• Year-over-year, Current Deferred Revenue plunged 80.0% in 2020 and advanced 16.0% in 2022.
• Over 5 years, Current Deferred Revenue stood at $711000.0 in 2018, then dropped by 29.68% to $500000.0 in 2019, then sank by 80.0% to $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then increased by 16.0% to $116000.0 in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $116000.0 in Q1 2022, $100000.0 in Q4 2021, and $100000.0 in Q3 2021.